MTOR and neoplasm: It was recently reported that insulin-like growth factor 1 (IGF-1), which can bind to IGF-1 receptor (IGF-1r) to activate phosphoinositide-3-kinase and activate both the phosphoinositide-dependent protein kinase-1 (PDK1) and mammalian targets of rapamycin (mTOR) rictor kinases, is involved in tumor development, including progression and angiogenesis.